Microba Life Sciences Ltd (map) Logo

Microba Life Sciences Ltd (MAP)

___:___ · Healthcare
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE

MAP Chart

Snapshot

MAP's Principal Activity is the microba is a commercial stage company with leading technology for measuring the human gut microbiome.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -
vs ASX 200 (1yr) -45.58%

Size

Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 1,254 of 2,413
Sector Rank 99 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies TDL / CYP / MXC
EPS $0.00
DPS $0.00
Book Value Per Share $0.00

Broker Consensus

MAP is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Announcements

Date Heading Pages File Size Time

Corporate Overview

Microba Life Sciences Limited is a precision microbiome company with leading technology developed at the University of Queensland. Microba provide its gut microbiome testing services globally through two service types - Personal Testing and Research Testing.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Brisbane QLD 4000
Website www.microba.com
Registry Automic Group
Auditor Pitcher Partners
Date Listed 5 Apr 2022

Upcoming Calendar (Forecasted)

No calendar entries available.

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Dr Caroline Popper Non-Executive Director Jan 2020

Dr Caroline Popper

Non-Executive Director

Dr Popper has more than 20 years of experience in the international diagnostics, medical devices and drug discovery fields, including 10 years in senior management and marketing roles at the medical technology firm, Becton Dickson & Company. Dr Popper has served in senior managerial and advisory positions at various Fortune 500 and start-up companies, including bioMerieux and MDS Proteomics.

Dr Hyungtae Kim Non-Executive Director Jun 2019

Dr Hyungtae Kim

Non-Executive Director

Dr Kim is an internationally experienced leader in the genomics field having held the positions of Chief Executive Officer of Macrogen, Inc., (Macrogen) from 2008 to 2014 and Chief Executive Officer of Macrogen Europe from 2015 to 2017. Dr Kim is now a Director of the Gongwu Genome Information Foundation. Dr Kim is a nominee Director of Macrogen, Inc.

Mr Richard Adam Bund Non-Executive Director Feb 2018

Mr Richard Adam Bund

Non-Executive Director

Mr Bund is a Director of Equipe Advisory accounting firm. Mr Bund has more than 20 years of experience in accounting and corporate finance and is the director of several private Australian companies. He is also a member of Risk committee.

Mr Pasquale (Paddy) Rombola Non-Executive Chairman,Non-Executive Director Jun 2017

Mr Pasquale (Paddy) Rombola

Non-Executive Chairman,Non-Executive Director

Mr Rombola has over 30 years of corporate and financial experience in Australia, Asia and the United Kingdom. He spent 19 years in senior positions with Morgan Stanley and Deutsche Bank, including 7 years in the role of Managing Director. Mr Rombola is a current Non-executive Director of Audeara Limited, a hearing health company (ASX: AUA), he is the Chair of Advantage Agriculture Pty Ltd, a private agribusiness company. He was also formerly the Chair and Director of Helix Resources Limited (ASX: HLX). He is also a member of Risk committee.

Professor Ian Hector Frazer Non-Executive Deputy Chairman,Non-Executive Director Jan 2017

Professor Ian Hector Frazer

Non-Executive Deputy Chairman,Non-Executive Director

Professor Frazer is a Professor at the University of Queensland and is the current Chair of the Australian Federal Government's Medical Research Future Fund. He is recognised as co-inventor of the technology enabling Gardasil - the vaccine currently used worldwide to help prevent cervical cancer. He also chairs Risk Committee.

Professor Gene William Tyson Non-Executive Director Jan 2017

Professor Gene William Tyson

Non-Executive Director

Professor Tyson is a Professor of Microbial Genomics at The Queensland University of Technology and was formerly the Deputy-Director of the Australian Centre for Ecogenomics. Whilst at the University of California, Berkeley he was involved in publishing the first paper regarding the use of metagenomic-sequencing for assessing microbial communities. Professor Tyson is also considered a world leading expert in microbial analysis.

Mr Peter Webse Joint Company Secretary N/A
Dr Luke Reid Chief Executive Officer N/A
Mr James Heath Chief Financial Officer,Joint Company Secretary N/A
Luke Reid Chief Executive Officer N/A

Director Transactions

MAP directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
07/04/22 Ian Frazer Buy +70,000 $0.424 $29,680 On-market trade
07/04/22 Pasquale (Paddy) Rombola Buy +44,445 $0.392 $17,443 On-market trade

Director Interests

The current holdings of MAP directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Ian Frazer 07/04/2022 222,222 1,004,144 300,000 N/A
Pasquale (Paddy) Rombola 07/04/2022 N/A 5,100,000 300,000 N/A
Hyungtae Kim 14/06/2019 N/A 17,828,431 200,000 N/A
Gene Tyson N/A N/A N/A N/A N/A
Richard Bund N/A N/A N/A N/A N/A
Caroline Popper N/A N/A N/A N/A N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Mar 29, 2022.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Sa Microba Holdings Pty Ltd 31,524,277 11.49%
Macrogen Inc 17,828,431 6.50%
Boysenholtz Pty Ltd 17,178,431 6.26%
Genenika Pty Ltd <The Tyson A/C> 17,100,000 6.23%
Dempsey Capital Pty Ltd <The Alium Alpha Fund A/C> 14,985,993 5.46%
Bnp Paribas Nominees Pty Ltd <Drp A/C> 12,482,493 4.55%
National Nominees Limited 11,666,666 4.25%
Ginkgo Bioworks Inc 10,886,385 3.97%
Tiga Trading Pty Ltd 7,334,734 2.67%
Mainstream Fund Services P/L <Peren Prvt To Pub Op/F A/C> 6,992,297 2.55%
Mainstream Fund Services P/L <Perennial Priv Of No 3 A/C> 6,375,000 2.32%
HSBC Custody Nominees (Australia) Limited A/C 2 6,308,334 2.30%
Mainstream Fund Services P/L <Perennial Priv Fnd 2 A/C> 5,357,142 1.95%
Rombola Family Pty Ltd <Rombola Family A/C> 5,055,555 1.84%
Sandhurst Trustees Limited <Jm Equities Consolidated A/C> 3,571,429 1.30%
Uniquest Pty Ltd 3,424,643 1.25%
Vernon Alan Wills <The Wills Family A/C> 3,222,222 1.17%
Australian Direct Investments Pty Limited <Super Fund A/C> 3,070,729 1.12%
Derp Enterprises Pty Ltd <The Angel Barnett Family A/C> 2,902,500 1.06%
Adam Skarshewski 2,900,000 1.06%
Wyeast Pty Ltd <The Rinke Family A/C> 2,900,000 1.06%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 0 76 45 265 163 549

Substantial Shareholders

No Substantial Shareholders for MAP in our database.

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
05-04-22 Macrogen Inc 17,828,431 -- 6.50
05-04-22 Perennial Value Management Limited 40,651,376 -- 14.82
05-04-22 Genenika Pty Ltd 17,100,000 -- 6.23
05-04-22 Boysenholtz Pty Ltd 17,178,431 -- 6.26
05-04-22 SA Microba Holdings Pty Ltd 31,524,277 -- 11.49
05-04-22 Alium Alpha Fund 19,874,882 -- 7.24

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Date Name Sold Previous % New %
06-05-22 Perennial Value Management Limited 3,000,000 14.8 13.7

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
No Financial Year End data available
MAP Historical Price Data (CSV)
Up to 20 years of EOD share price history
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.